Cosmo Reports Double-Digit Recurring Revenue Growth in H1 2026, Advances Clascoterone 5% Topical Solution Toward Regulatory Submission, and Confirms Full-Year Guidance
Ad hoc announcement pursuant to Art. 53 LR Recurring revenues from Winlevi® up 38%, Lialda® up 35%, and CDMO up 14% year-over-year Clascoterone Phase III 12-month data support chronic use, with regulatory submissions underway in the US and in Europe Debt-free with more than €205 million in cash, cash equivalents and investments
Soins de santé et hôpitaux, Santé
2026-07-23 1:01 AM EDT | Cosmo Pharmaceuticals N.V.
medmix Strengthens Profitability and Cash Flow While Advancing Growth and Efficiency Initiatives
Baar, Switzerland--(Newsfile Corp. - July 23, 2026) - Ad hoc announcement pursuant to Art. 53 LR MEDIA RELEASE Ad hoc announcement pursuant to Art. 53 LR Half-Year 2026 Results
Technologies, Construction / bâtiments, Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques
2026-07-23 12:09 AM EDT | medmix AG
Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 12:30 PM EDT | Phio Pharmaceuticals Corp.
Breathe BioMedical Expands Multi-Center Clinical Study in Breast Cancer to Canada
New Brunswick and Cambridge, Massachusetts--(Newsfile Corp. - July 22, 2026) - Breathe BioMedical, a company developing a breath analytics platform for early disease detection, today announced that Vitalité Health Network has joined as the first Canadian site in its large multi-center observational data collection study to advance the development of its t
Technologies, Biotechnologies, Soins de santé et hôpitaux, Santé
2026-07-22 10:00 AM EDT | Breathe BioMedical Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - July 22, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA platform, including its lead clinical candidate PH-762
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-22 7:00 AM EDT | Phio Pharmaceuticals Corp.
Envoy Medical Surpasses Three-Month Visit Milestone for All 56 Patients in Pivotal Clinical Trial
White Bear Lake, Minnesota--(Newsfile Corp. - July 21, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it has surpassed the three-month milestone for all 56 patients enrolled in the Company's pivotal clinical trial evaluating the investigational fully implanted Acclaim® cochlear implant. This marks another important clinical trial milestone as the Company
Biotechnologies, Soins de santé et hôpitaux
2026-07-21 9:17 AM EDT | Envoy Medical, Inc.
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors
King of Prussia, Pennsylvania--(Newsfile Corp. - July 21, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio is pleased to announce that R. Todd Plott, M.D. has been appointed to the Board of Directors of Phio Pharmaceuticals. Todd Plott, MD, is a board-certified dermatologist, accomplished researcher, inventor, an
Biotechnologies, Soins de santé et hôpitaux, Pharmaceutique, Santé
2026-07-21 7:00 AM EDT | Phio Pharmaceuticals Corp.
Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld
Bubendorf, Switzerland--(Newsfile Corp. - July 21, 2026) - Bachem (SIX: BANB) announced today the sig
Biotechnologies, Produits chimiques, Soins de santé et hôpitaux, Pharmaceutique
2026-07-21 12:40 AM EDT | Bachem Holding AG
Richards Group Inc. Announces July 2026 Dividend
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - Richards Group Inc. (TSX: RIC) (the "Company") announced today its cash dividend for the month ended July 31, 2026 of Cdn$0.11 per share. This dividend will be to shareholders of record at the close of business on July 31, 2026 and will be payable on August 14, 2026. Shareholders who are non-residents of Canada may be required to pay all withholding taxes payable in respect of any dividends of income by the Company, whether such dividends
Soins de santé et hôpitaux, Produits ménagers / de consommation / cosmétiques, Pharmaceutique
2026-07-20 3:54 PM EDT | Richards Group Inc.
ALZAI Health Corp. Secures Exclusive Global License for AI-Driven Liver Disease Risk Identification Technology
Toronto, Ontario--(Newsfile Corp. - July 20, 2026) - ALZAI Health Corp. (TSXV: ALZI) ("ALZAI" or the "Company"), is pleased to announce that it has entered into an exclusive worldwide license agreement (the "Agreement") with MOR Research Applications Ltd. ("MOR"), the technology transfer company of Clalit Health Services and Yeda Research, the technology transfer company of the Weizmann Institute of Science and Development Co. Ltd. ("Yeda"), for proprietary artificial intelligence-driven live
Technologies, Logiciels, Soins de santé et hôpitaux
2026-07-20 6:00 AM EDT | Alzai Health Corp.
LevelJump Announces Revocation of Cease Trade Order; Seeking Reinstatement of Trading on TSX Venture Exchange
Toronto, Ontario--(Newsfile Corp. - July 17, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company") is pleased to announce that, further to its news release of April 30, 2026, the Ontario Securities Commission has revoked a cease trade order that had been originally issued against the Company on May 6, 2026. The Company is now current on its continuous disclosure obligations under securities legislation. The Company is now in the process
Soins de santé et hôpitaux, Santé
2026-07-17 6:55 PM EDT | LevelJump Healthcare Corp.
Trenchant Technologies Capital Corp. Announces Delay of Annual Filings and Application for MCTO Application
Vancouver, British Columbia--(Newsfile Corp. - July 17, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (OTC Pink: AITTF) ("Trenchant" or the "Company") announces that it will be delaying the filing of its audited annual financial statements for the year ended March 31, 2026, the related management's discussion and analysis, and related CEO and CFO certificates (collectively, the "Required Filings") beyond the July 29, 2026 filing deadline. The delay is res
Technologies, Services bancaires / financiers, Biotechnologies, Soins de santé et hôpitaux
2026-07-17 4:50 PM EDT | Trenchant Technologies Capital Corp.
Discovery Senior Living Announces Changes in Executive Finance Leadership
Bonita Springs, Florida--(Newsfile Corp. - July 16, 2026) - Discovery Senior Living (Discovery or the Company) and its affiliated companies, one of the nation's largest and most trusted senior housing operators, today announced two strategic executive finance leadership appointments to further strengthen the Company's accounting platform and expand its institutional capabilities in support of an increasingly sophisticated operating environment. Effective July 8, Elizabeth Redmond, CPA,
Soins de santé et hôpitaux, Immobilier, Logement
2026-07-16 3:10 PM EDT | Discovery Senior Living
CareRx Corporation to Host Second Quarter 2026 Financial Results Conference Call on Thursday, July 30, 2026 at 8:30 a.m. ET
Toronto, Ontario--(Newsfile Corp. - July 16, 2026) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company") today announced it will host a conference call to discuss its second quarter 2026 financial results on Thursday, July 30, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its second quarter 2026 financial results for the period ended June 30, 2026, after market close on Wednesday, July 29, 2026. Telephone Dial-In Access I
2026-07-16 7:00 AM EDT | CareRx Corporation
Aurora Spine and CornerLoc Announce Strategic Commercial Alliance to Expand Minimally Invasive Spine and SI Joint Solutions Nationwide
California and Tulsa, Oklahoma--(Newsfile Corp. - July 16, 2026) - Aurora Spine Corporation ("Aurora Spine" or the "Company") (TSXV: ASG) (OTCQB: ASAPF), a leader in the development of groundbreaking medical devices for spinal surgery and Foundation Fusion Solutions, LLC dba CornerLoc, founded on one idea: provide patients with an intelligent and lasting solution for SI joint fusion, today announced the formation of a Strategic Commercial Alliance designed to expand physician access
2026-07-16 6:50 AM EDT | Aurora Spine Corporation
Jett Foundation Announces Capital Campaign for 'Jett's Place,' a First-of-Its-Kind Sanctuary for Duchenne Muscular Dystrophy Community
Norwell, Massachusetts--(Newsfile Corp. - July 15, 2026) - Jett Foundation announced its most ambitious milestone to date: the launch of a capital campaign to fund the building of Jett's Place, a premier wellness and retreat center serving as a dedicated sanctuary for individuals and families affected by Duchenne muscular dystrophy (DMD). The fundraising campaign was anchored in its initial phase by two transformative $1 million donations from the Emilson Family and ITF Therapeutics. To
2026-07-15 3:43 PM EDT | The Jett Foundation
Veritas Association Management Earns Prestigious AMC Institute Accreditation
Chicago, Illinois--(Newsfile Corp. - July 15, 2026) - Veritas Association Management has been awarded accreditation by the AMC Institute, the global trade association representing the Association Management industry. This distinction places the healthcare-focused association management company among an elite group of firms recognized for meeting the industry's highest standards of operational performance, ethical practices and client service. Among more than 500 association management
2026-07-15 10:20 AM EDT | Veritas Association Management
Discovery Senior Living Introduces Enhanced Segmentation Framework to Further Strengthen Its Operating Platform and Drive Performance Across Communities
Bonita Springs, Florida--(Newsfile Corp. - July 15, 2026) - Discovery Senior Living ("Discovery" or "the Company") and its affiliated companies, one of the largest and most trusted seniors housing operators in the U.S., is pleased to announce the next evolution of its operating platform with the introduction of a fully integrated, portfolio-wide segmentation and program delivery framework designed to further enhance performance, scalability, and operational excellence across its Independent L
Soins de santé et hôpitaux, Immobilier, Logement
2026-07-15 10:01 AM EDT | Discovery Senior Living
Adia Med Inc. (Formerly Adia Nutrition Inc.) Launches Redesigned Corporate Website
Winter Park, Florida--(Newsfile Corp. - July 15, 2026) - Adia Med Inc. (OTCQB: ADIA), a clinical-stage regenerative medicine company, today announced the launch of its redesigned corporate website. The redesigned website is now live, with the project still in progress and active changes and improvements currently being made.
Soins de santé et hôpitaux, Santé
2026-07-15 9:30 AM EDT | Adia Med Inc.
WELL Health Closes $150 Million, 5-Year Senior Unsecured Notes Offering
Vancouver, British Columbia--(Newsfile Corp. - July 15, 2026) - WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) (the "Company" or "WELL"), a digital health company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, announces it has closed its previously announced inaugural private placement offering (the "Offering") of $150 million aggregate principal amount of 6.875% senior u
Technologies, Logiciels, Soins de santé et hôpitaux, Santé
2026-07-15 9:00 AM EDT | WELL Health Technologies Corp.